TuHURA Biosciences Inc (HURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has a cash flow conversion efficiency ratio of -0.190x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.41 Million) by net assets ($23.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HURA equity to assets ratio to measure how much of total assets are equity-financed.
TuHURA Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2026)
This chart illustrates how TuHURA Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore TuHURA Biosciences Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
TuHURA Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TuHURA Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tung Thih Electronic Co Ltd
TWO:3552
|
0.091x |
|
Pyridam Farma Tbk
JK:PYFA
|
-0.213x |
|
Seoul Broadcasting System
KO:034120
|
0.025x |
|
AYER Holdings Bhd
KLSE:2305
|
0.075x |
|
Western Forest Products Inc
TO:WEF
|
0.000x |
|
Empresas Iansa S.A
SN:IANSA
|
0.106x |
|
Baozun Inc
NASDAQ:BZUN
|
0.000x |
|
De Licacy Industrial Co Ltd
TW:1464
|
0.054x |
Annual Cash Flow Conversion Efficiency for TuHURA Biosciences Inc (2015–2026)
The table below shows the annual cash flow conversion efficiency of TuHURA Biosciences Inc from 2015 to 2026. For the full company profile with market capitalisation and key ratios, see HURA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $20.93 Million | $-27.63 Million | -1.320x | -30.79% |
| 2025-06-30 | $14.59 Million | $-14.73 Million | -1.009x | -121.92% |
| 2024-06-30 | $-1.56 Million | $-7.18 Million | 4.604x | +854.42% |
| 2023-06-30 | $12.30 Million | $-7.51 Million | -0.610x | -106.95% |
| 2022-06-30 | $-747.82K | $-6.56 Million | 8.777x | +592.39% |
| 2021-06-30 | $10.58 Million | $-18.86 Million | -1.782x | +94.09% |
| 2020-06-30 | $263.00K | $-7.93 Million | -30.144x | -837.35% |
| 2019-06-30 | $1.97 Million | $-6.33 Million | -3.216x | -77.44% |
| 2018-06-30 | $5.44 Million | $-9.85 Million | -1.812x | -48.68% |
| 2017-06-30 | $6.58 Million | $-8.02 Million | -1.219x | -15.10% |
| 2016-06-30 | $4.86 Million | $-5.15 Million | -1.059x | -122.58% |
| 2015-06-30 | $-821.49K | $-3.85 Million | 4.690x | -- |
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more